SCHEDULE 13G: Morgan Stanley Discloses 5.4% Stake in C4 Therapeutics, Inc.

Morgan Stanley has filed a Schedule 13G, reporting a 5.4% beneficial ownership stake in C4 Therapeutics, Inc. as of December 31, 2024.

Summary

• Morgan Stanley reported beneficial ownership of 3,828,810 shares of C4 Therapeutics, Inc. Common Stock.
• This ownership represents 5.4% of the total class of securities.
• The filing date for this Schedule 13G is February 3, 2025, with the event date requiring the filing being December 31, 2024.
• Morgan Stanley holds shared voting power over 3,828,148 shares and shared dispositive power over 3,828,810 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of C4 Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The filing is a routine compliance disclosure of beneficial ownership by a major financial institution, which can be interpreted as a neutral to slightly positive signal due to the institutional stake.

Positives

• A major financial institution, Morgan Stanley, has taken a significant stake, which can be interpreted as a vote of confidence in C4 Therapeutics, Inc.

Negatives

• No specific negative information is disclosed in this routine ownership filing.

Risks

• The filing explicitly states that the securities were not acquired for the purpose of changing or influencing control of C4 Therapeutics, Inc., mitigating concerns about hostile takeover attempts from this specific stake.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding C4 Therapeutics, Inc.'s future outlook.

Management Comments

• This filing is an ownership disclosure by Morgan Stanley and does not include comments from C4 Therapeutics, Inc. management.

Industry Context

This filing is a routine ownership disclosure and does not provide specific industry context or analysis related to C4 Therapeutics, Inc.'s operations or the broader industry trends.

Comparison to Industry Standards

• This document, a Schedule 13G, is a disclosure of beneficial ownership and does not contain information for comparison to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Increased institutional ownership by Morgan Stanley may be viewed positively, potentially signaling confidence in the company.

Next Steps

• This filing does not outline future actions, events, or milestones for C4 Therapeutics, Inc. or Morgan Stanley beyond the ownership disclosure.

Key Dates

Keywords

C4 Therapeutics, Morgan Stanley, Schedule 13G, beneficial ownership, institutional investor, common stock, SEC filing